The Imprecision of “Precision Medicine” in Pancreatic Adenocarcinoma

Stefano Cascinu

DOI: https://doi.org/10.7175/cmi.v14i1.1463

Full Text

HTML PDF

References

  • Bray F, Ferlay J, Soerjomataram J, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424; https://doi.org/10.3322/caac.21492
  • Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25; https://doi.org/10.1056/NEJMoa1011923
  • Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703; https://doi.org/10.1056/NEJMoa1304369
  • Aguirre AJ, Nowak JA, Camarda ND, et al. Real time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov 2018; 8: 1096-111; https://doi.org/10.1158/2159-8290.CD-18-0275
  • Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317-27; https://doi.org/10.1056/NEJMoa1903387
  • O’Reilly EM, Lee JW, Zalupski M, et al. Randomized multicenter Phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020; [published online ahead of print, 2020 Jan 24]; https://doi.org/10.1200/JCO.19.02931
  • Pishvaian MJ, Brody JR, Lyons E, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecule profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020; S1470-2045(20)30074-7; [published online ahead of print, 2020 Mar 2]; https://doi.org/10.1016/S1470-2045(20)30074-7
  • Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52; https://doi.org/10.1038/nature16965
  • Chan-Seng M, Jaeseung C, Kim L, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Gen 2020; 52: 231-40; https://doi.org/10.1038/s41588-019-0566-9
  • Rhim AD, Mirek ET, Aiello NM, et al. EMT dissemination precede pancreatic tumor formation. Cell 2012: 148: 349-61; https://doi.org/10.1016/j.cell.2011.11.025
  • Porter RL, Magnus NKC, Thapar V, et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019; 116: 26835-45; https://doi.org/10.1073/pnas.1914915116

Statistics

Abstract: 38 views
HTML: 25 views
PDF: 13 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


© SEEd srl